Aug 8 (Reuters) - Genmab A/S GMAB.CO:
GENMAB REVENUE INCREASED19% COMPARED TO FIRST SIX MONTHS OF 2024, TO $1,640 MILLION
OPERATING PROFIT INCREASED TO $548 MILLION IN H1 2025
DARZALEX SALES UP 22% TO $6,776 MILLION IN H1 2025
UPDATES 2025 GUIDANCE DUE TO DARZALEX ROYALTIES
2025 FY OUTLOOK OPERATING PROFIT $1,055 - $1,405
REVISED 2025 FY 3,500 USD MILLION - 3,700 USD MILLION
Source text: ID:nGNE5V8BjK
Further company coverage: GMAB.CO
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))